A phase I dose ranging study of the safety, tolerability and immunogenicity of a 3-dose regimen of the MRKAd5 HIV-1 trigene [V 520] and the MRKAd6 HIV-1 trigene [V 526] vaccines alone and in combination in healthy adults.
Latest Information Update: 10 May 2022
At a glance
- Drugs V 520 (Primary) ; V 526
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme Corp.
- 26 Feb 2009 Status changed from not stated to active, no longer recruiting.
- 24 Feb 2009 New source identified and integrated (ClinicalTrials.gov); planned end date is 1 Mar 2011.
- 20 Mar 2007 New trial record.